TOKYO (Reuters) -Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Chief Executive Vas Narasimhan said in an interview with The Wall Street Journal. “The bar is very high, we need to find something that’s truly differentiated, that brings something new ...

(Bloomberg) -- Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) is keeping a close eye on the U.S. tariff policy proposed by the Biden ...

New CEO Vas Narasimhan wants to cut Novartis' R&D costs by using digital tech – and with this in mind the firm has scaled up a project involving virtual clinical trials. The Swiss pharma company ...

Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early April, Chief Executive Vas Narasimhan said on Monday.

Chief Executive Vas Narasimhan said on Monday. U.S. President Donald Trump last month flagged potential import duties of about 25% on pharmaceuticals as part of measures affecting a range of ...